BeiGene Ltd, a leading China-based biotechnology company (NASDAQ: BGNE; HKG: 6160; SHA: 688235), has announced the first prescription of its programmed death-1 (PD-1) inhibitor, Tevimbra (tislelizumab), in the United States. This marks a significant milestone for the company as it expands its global reach.
Tislelizumab received approval in the US in March of this year for the treatment of patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who have been previously treated with systemic chemotherapy but have not received prior PD-(L)1 inhibitor treatment. The launch of tislelizumab in the US offers a more affordable option for this patient population, with a price point set at 10% lower than other PD-1 therapies approved for this indication.
The drug has also gained registration in the European Union, United Kingdom, the US, South Korea, Switzerland, Australia, and other regions. In April of this year, tislelizumab was approved in the EU for the treatment of first-line and second-line non-small cell lung cancer. Market filings for first-line gastric/gastroesophageal junction (G/GEJ) and first-line ESCC are currently under review in both the US and EU. Recently, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval for these two indications.- Flcube.com
